Palliative Second-line Treatment with Weekly High-dose 5-Fluorouracil As 24-hour Infusion and Folinic Acid (AIO) plus Oxaliplatin after Pre-treatment with the AIO-Regimen in Colorectal Cancer (CRC)

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 385-391

  Link, K ^a   Happich, K ^a   Schirner, I ^a   Jungert B ^a   Bruckl V ^a   Mannlein G ^a   Bruckl W M ^a   Merkel, S ^a   Gohl J ^a   Hohenberger, W ^a   Hahn, E G ^a   Wein, A ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Colorectal cancer; Oxaliplatin; Palliative first and second line treatment; Weekly high dose 5 FU as 24 hour infusion and folinic acid

Indexed keywords

FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE;

EID: 10744226209     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. McKean-Cowdin R, Feigelson SH, Ross RK, Pike MC and Henderson BE: Declining cancer rates in the 1990s. J Clin Oncol 18: 2258-2268, 2000.
2. Schmiegel W, Adler G, Frühmorgen P, Fölsch P, Graeven U, Layer P et al: Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung-Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen. Z Gastroenterol 38: 49-75, 2000.
3. Ott R, Wein A and Hohenberger W: Lebermetastasen - primäre oder multimodale Therapie? Chirurg 72: 887-897, 2001.
4. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
5. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998.
6. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D and Hecht JR: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807-814, 2003.
7. De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
8. André T, Louvet C, Raymond E, Tournigand C and de Gramont A: Bimonthly high-dose leucorovin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9: 1251-1253, 1998.
9. André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560-3568, 1999.
10. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL et al on behalf of GERCOR: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 35: 1338-1342, 1999.
11. Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Mabro M et al for the Oncology Multidisciplinary Research Group (GERCOR): High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37: 1000-1005, 2001.
12. Ducreux M, Ychou M, Seitz J-F, Bonnay M, Bexon A, Armand J-P et al: Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 17: 2901-2908, 1999.
13. Hofheinz R, Hartung G, Samel S, Emig M, Pilz L, Willeke F et al: Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer - a phase II study. Anticancer Drugs 13: 999-1004, 2002.
14. Tournigand C, Louvet C, Quinaux E, André T, Lledo G, Flesch M et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol 20: 494, 2001.
15. Wein A, Lehnert T, Liersch T, Reingruber B, Schaible A, Schenk J et al: Quality controlled surgery in adjuvant treatment of colon cancer (CC) UICC III: InTACT - a multicenter phase III trial. Ann Oncol 13: 268P, 2002.
16. World Health Organization: Handbook for Reporting Results of Cancer Treatment. Geneva, WHO Offset Publication 48, 1979.
17. Hartung G, Hofheinz R-D, Wein A, Riedel C, Rost A, Fritze D et al: Phase II-study of a weekly 24-h-infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. Onkologie 24: 457-462, 2001.
18. Wein A, Riedel C, Köckerling F, Martus P, Baum U, Brueckl WM et al: Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 12: 1721-1727, 2001.
19. Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A et al: Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23: 1773-1778, 2003.
20. Greenwood M: The Natural Duration of Cancer. Rep. Publ. Hith. Med. Subj., No. 33. London: HM Stationary Office, 1926.
21. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidi J et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
22. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003.
23. Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK et al: N9741: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5-FU)/ leucovorin (LV) or Oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 21: 511, 2002.
24. Wein A, Riedel C, Brückl W, Merkel S, Ott R, Hanke B et al: Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-h infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64: 131-138, 2003.
25. Bleiberg H, Brienza S, Gerard B, Di Leo A, Hendlisz A, Van Daele D et al: Oxaliplatin combined with a high dose, 24-hour continuous 5-FU infusion and folinic acid based regimen in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 18: 925, 1999.
26. Buechele T, Balleisen L, Beck M, Eckart M, Eisenhauer T, Heike M et al: Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU/FA in patients (Pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 18: 176, 1999.
27. Janinis J, Papakostas P, Samelis G, Skarlos D, Papagianopoulos P and Fountzilas G: Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 11: 163-167, 2000.
28. Van Cutsem E, Szanto J, Roth A, Humblet Y, Köhne C-H, Wils J et al: Evaluation of the addition of oxaliplatin (OXA) to the same Mayo or German 5FU regimen in advanced refractory colorectal cancer (ARCRC). Proc Am Soc Clin Oncol 18: 900, 1999.
29. Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V et al. for the Oncology Multidisciplinary Research Group (GERCOR): Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 11: 1477-1438, 2000.
30. Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L et al: Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 13: 1558-1567, 2002.